ChinaBio® Partnering Forum
June 24-25, 2009 | Shanghai, China
China has remained one of the few bright spots during the global financial crisis with GDP growth still at 9%. While VC investment in biotech and life science companies has slowed somewhat, big pharma and biotech are demonstrating a healthy appetite for funding novel, early stage technologies. Pfizer, Roche, Merck and others have established licensing and partnering offices in Shanghai specifically to seek out these opportunities.
Partnering is becoming a significant source of funding for technology development and early and mid-stage companies in China.
China life science companies, universities and institutes have completed more partnering deals in the 1st 10 months of 2008 than all of 2007 and the number of M&A deals has doubled. And the value of these deals can be significant – from $1 million to over $1 billion USD.
If you’re a scientist, entrepreneur or established company in China with
novel drug development, drug delivery, diagnostic or medical device technologies, then big pharma and biotech want to meet you.
Our ChinaBio® Investor Forums have helped China life science companies secure over $60 million in funding in 2008. HD Biosciences, CrownBio, PegBio, ChiralQuest, GenePharma are just a few of our presenting companies that have secured funding from Lilly, Pfizer, Merck, Roche and others.
Now, to meet the need of developers of early stage technology seeking funding, and big pharma and biotech companies seeking partnership opportunities, ChinaBio® Accelerator will host its first ChinaBio® Partnering Forum in Shanghai. This event will bring together over 300 attendees seeking partnership deals. More than 50 novel technologies from universities, institutes and companies from throughout China will have the opportunity to meet with nearly all the major pharma companies, many of China’s own biopharma, biotech and medical device companies, 50+ VCs, and many others interested in licensing or commercializing novel technologies.
Technology areas represented will include: novel targets, leads and molecules, biomarkers, diagnostics, drug development platforms, drug delivery systems and medical devices (orthopaedic, imaging, POC, monitoring, etc.) All technologies will be pre-screened by ChinaBio® to ensure the high quality our events have become known for.
This jam-packed 2-day forum will offer a variety of partnership opportunities:
1. One-on-one meetings: all attendees will be able to request one-on-one meetings with companies seeking partnerships by technology area;
2. Technology presentations: entrepreneurs and researchers will present their technologies to attendees in 15 minute sessions or during one of four poster sessions;
3. Company presentations: big pharma and other companies seeking technologies will present their areas of interest and approach to partnership; and
4. Exhibits and poster sessions: entrepreneurs and researchers will be available in the afternoons with displays and information on their technologies and companies.
Presentations and Workshops
In addition, there will be a number of keynote presentations and workshops on topics important to everyone involved in China’s life science industry, including:
• Keynote Presentations:
♦ The State of China’s Life Science Industry: Greg B. Scott, President, ChinaBio Accelerator
♦ The Funding Gap – where to find funding for early stage technology development
• Executive Workshops:
♦ Securing Global IP – how to make sure your technologies are protected
♦ Corporate Structure – how to structure a life science company in China
♦ Doing the Deal – what to look for in deal terms when partnering/licensing
♦ Pre-clinical Studies – how to move your technology from the lab to the clinic
♦ Clinical Trials – the ins and outs of doing clinical trials in China
♦ Regulatory Hurdles – how to deal with the SFDA and FDA to ensure approval